BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29462322)

  • 1. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Rinke de Wit TF; Paredes R
    J Antimicrob Chemother; 2018 May; 73(5):1167-1172. PubMed ID: 29462322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.
    De Francesco MA; Izzo I; Properzi M; Gargiulo F; Caccuri F; Quiros-Roldan E; Castelli F; Caruso A; Focà E
    AIDS Res Hum Retroviruses; 2018 Jul; 34(7):570-574. PubMed ID: 29631420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
    McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ
    AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary resistance to integrase strand-transfer inhibitors in Europe.
    Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
    J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance-Associated Mutations and Polymorphisms among Integrase Inhibitor-Naïve HIV-1 Patients in Kuwait.
    Chehadeh W; Albaksami O; John SE; Al-Nakib W
    Intervirology; 2017; 60(4):131-137. PubMed ID: 29212076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
    Wenk BM; Mbunkah HA; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Leemann C; Metzner KJ
    J Antimicrob Chemother; 2021 Jan; 76(1):124-129. PubMed ID: 32954411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China.
    Liu L; Dai L; Yao J; Pan P; Li L; Liu Z; An X; Sun L; Wu H; Su B; Zhang T
    AIDS; 2019 Oct; 33(12):1945-1947. PubMed ID: 31491787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen.
    Masoud S; Kamori D; Barabona G; Mahiti M; Sunguya B; Lyamuya E; Ueno T
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):539-543. PubMed ID: 32126792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
    Chang SY; Lin PH; Cheng CL; Chen MY; Sun HY; Hsieh SM; Sheng WH; Su YC; Su LH; Chang SF; Liu WC; Hung CC; Chang SC
    Sci Rep; 2016 Oct; 6():35779. PubMed ID: 27779200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.
    Mikasi SG; Gichana JO; Van der Walt C; Brado D; Obasa AE; Njenda D; Messembe M; Lyonga E; Assoumou O; Cloete R; Ikomey GM; Jacobs GB
    AIDS Res Hum Retroviruses; 2020 May; 36(5):450-455. PubMed ID: 31830799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
    Kirichenko A; Lapovok I; Baryshev P; van de Vijver DAMC; van Kampen JJA; Boucher CAB; Paraskevis D; Kireev D
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32752001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
    Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
    HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection.
    Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Blanco JL; Mosquera MM; Peñafiel J; Gatell JM; Marcos MA; Miró JM
    J Antimicrob Chemother; 2017 Jan; 72(1):205-209. PubMed ID: 27624569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania.
    Henerico S; Lyimo E; Makubi AN; Magesa D; Desderius B; Mueller A; Changalucha J; Kalluvya SE; Van Zyl G; Preiser W; Mshana SE; Kasang C
    J Antimicrob Chemother; 2022 Oct; 77(11):3138-3143. PubMed ID: 36101479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
    Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
    Abram ME; Ram RR; Margot NA; Barnes TL; White KL; Callebaut C; Miller MD
    PLoS One; 2017; 12(2):e0172206. PubMed ID: 28212411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.